Dengue Vaccine Market Size, Share, and Outlook, H2-2025 Report- By Category (Live Attenuated Vaccines, Chimeric Live Attenuated Vaccines), By Product (CTD-TDV, Others), By Route of Administration (Subcutaneous, Others), By Application (Hospitals and clini
Description
Dengue Vaccine Market Outlook
The global Dengue Vaccine Market Size is valued at $842.1 Million in 2025 and is forecast to reach $2323.1 Million in 2032 at a CAGR of 15.6%.
The Dengue Vaccine Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Dengue Vaccine Market segments across 22 countries from 2021 to 2032. Key segments covered include By Category (Live Attenuated Vaccines, Chimeric Live Attenuated Vaccines), By Product (CTD-TDV, Others), By Route of Administration (Subcutaneous, Others), By Application (Hospitals and clinic, Government Institutes, Specialty Clinics, Others), By End-User (Healthcare, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Dengue Vaccine Market Insights, 2025
In 2025, the dengue vaccine market is expanding with new approvals and broader rollouts across endemic regions in Asia, Latin America, and parts of Africa. Next-generation vaccines with tetravalent protection are showing improved efficacy across all serotypes, addressing limitations of earlier formulations. National immunization programs are increasingly incorporating dengue vaccination for school-aged children in high-burden areas, supported by WHO guidance. Combination vector control and vaccination campaigns are being piloted to reduce overall disease incidence. Supply chain resilience is being prioritized, with manufacturers building regional production hubs to meet seasonal demand spikes. Pharmacovigilance systems are closely monitoring adverse events to ensure public confidence in large-scale immunization efforts.
Five Trends Shaping the Global Dengue Vaccine Market in 2025 and Beyond
The global Dengue Vaccine Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Dengue Vaccine Industry?
The Dengue Vaccine Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Dengue Vaccine Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Dengue Vaccine Market Segment Insights
The Dengue Vaccine Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Category (Live Attenuated Vaccines, Chimeric Live Attenuated Vaccines), By Product (CTD-TDV, Others), By Route of Administration (Subcutaneous, Others), By Application (Hospitals and clinic, Government Institutes, Specialty Clinics, Others), By End-User (Healthcare, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Dengue Vaccine Industry Value Chain
The chapter identifies potential companies and their operations across the global Dengue Vaccine Industry ecosystem. It assists decision-makers in evaluating global Dengue Vaccine Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Dengue Vaccine Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Dengue Vaccine Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Dengue Vaccine Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Dengue Vaccine Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Dengue Vaccine Market.
Europe Dengue Vaccine Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Dengue Vaccine Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Dengue Vaccine Industry competitiveness. The report analyses the key Dengue Vaccine Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Dengue Vaccine Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Dengue Vaccine Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Dengue Vaccine Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Dengue Vaccine Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Dengue Vaccine Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Dengue Vaccine Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Biological E Ltd, GeneOne Life Science Inc, GlaxoSmithKline Plc, Medigen Vaccine Biologics Corp, Merck & Co. Inc, Panacea Biotec Ltd, Sanofi Pasteur Ltd, Serum Institute of India Pvt. Ltd, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Dengue Vaccine Market Scope
Leading Segments
By Category
Live Attenuated Vaccines
Chimeric Live Attenuated Vaccines
By Product
CTD-TDV
Others
By Route of Administration
Subcutaneous
Others
By Application
Hospitals and clinic
Government Institutes
Specialty Clinics
Others
By End-User
Healthcare
Others
Leading Companies
Biological E Ltd
GeneOne Life Science Inc
GlaxoSmithKline Plc
Medigen Vaccine Biologics Corp
Merck & Co. Inc
Panacea Biotec Ltd
Sanofi Pasteur Ltd
Serum Institute of India Pvt. Ltd
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Company Ltd
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report Make informed decisions with 12-year forecasts across 22 countries and multiple market segments. Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry. Gain insights into the competitive landscape, including company profiles, financials, and strategic moves. Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations. Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade. Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions. Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
The global Dengue Vaccine Market Size is valued at $842.1 Million in 2025 and is forecast to reach $2323.1 Million in 2032 at a CAGR of 15.6%.
The Dengue Vaccine Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Dengue Vaccine Market segments across 22 countries from 2021 to 2032. Key segments covered include By Category (Live Attenuated Vaccines, Chimeric Live Attenuated Vaccines), By Product (CTD-TDV, Others), By Route of Administration (Subcutaneous, Others), By Application (Hospitals and clinic, Government Institutes, Specialty Clinics, Others), By End-User (Healthcare, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Dengue Vaccine Market Insights, 2025
In 2025, the dengue vaccine market is expanding with new approvals and broader rollouts across endemic regions in Asia, Latin America, and parts of Africa. Next-generation vaccines with tetravalent protection are showing improved efficacy across all serotypes, addressing limitations of earlier formulations. National immunization programs are increasingly incorporating dengue vaccination for school-aged children in high-burden areas, supported by WHO guidance. Combination vector control and vaccination campaigns are being piloted to reduce overall disease incidence. Supply chain resilience is being prioritized, with manufacturers building regional production hubs to meet seasonal demand spikes. Pharmacovigilance systems are closely monitoring adverse events to ensure public confidence in large-scale immunization efforts.
Five Trends Shaping the Global Dengue Vaccine Market in 2025 and Beyond
The global Dengue Vaccine Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Dengue Vaccine Industry?
The Dengue Vaccine Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Dengue Vaccine Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Dengue Vaccine Market Segment Insights
The Dengue Vaccine Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Category (Live Attenuated Vaccines, Chimeric Live Attenuated Vaccines), By Product (CTD-TDV, Others), By Route of Administration (Subcutaneous, Others), By Application (Hospitals and clinic, Government Institutes, Specialty Clinics, Others), By End-User (Healthcare, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Dengue Vaccine Industry Value Chain
The chapter identifies potential companies and their operations across the global Dengue Vaccine Industry ecosystem. It assists decision-makers in evaluating global Dengue Vaccine Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Dengue Vaccine Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Dengue Vaccine Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Dengue Vaccine Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Dengue Vaccine Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Dengue Vaccine Market.
Europe Dengue Vaccine Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Dengue Vaccine Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Dengue Vaccine Industry competitiveness. The report analyses the key Dengue Vaccine Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Dengue Vaccine Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Dengue Vaccine Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Dengue Vaccine Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Dengue Vaccine Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Dengue Vaccine Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Dengue Vaccine Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Biological E Ltd, GeneOne Life Science Inc, GlaxoSmithKline Plc, Medigen Vaccine Biologics Corp, Merck & Co. Inc, Panacea Biotec Ltd, Sanofi Pasteur Ltd, Serum Institute of India Pvt. Ltd, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Dengue Vaccine Market Scope
Leading Segments
By Category
Live Attenuated Vaccines
Chimeric Live Attenuated Vaccines
By Product
CTD-TDV
Others
By Route of Administration
Subcutaneous
Others
By Application
Hospitals and clinic
Government Institutes
Specialty Clinics
Others
By End-User
Healthcare
Others
Leading Companies
Biological E Ltd
GeneOne Life Science Inc
GlaxoSmithKline Plc
Medigen Vaccine Biologics Corp
Merck & Co. Inc
Panacea Biotec Ltd
Sanofi Pasteur Ltd
Serum Institute of India Pvt. Ltd
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Company Ltd
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report
Table of Contents
183 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Dengue Vaccine Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Dengue Vaccine Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Dengue Vaccine Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Dengue Vaccine Market Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Dengue Vaccine Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Category
- Live Attenuated Vaccines
- Chimeric Live Attenuated Vaccines
- By Product
- CTD-TDV
- Others
- By Route of Administration
- Subcutaneous
- Others
- By Application
- Hospitals and clinic
- Government Institutes
- Specialty Clinics
- Others
- By End-User
- Healthcare
- Others
- 6. Global Dengue Vaccine Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Dengue Vaccine Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Dengue Vaccine Market Trends and Growth Opportunities
- 6.2.1 North America Dengue Vaccine Market Outlook by Type
- 6.2.2 North America Dengue Vaccine Market Outlook by Application
- 6.3 North America Dengue Vaccine Market Outlook by Country
- 6.3.1 The US Dengue Vaccine Market Outlook, 2021- 2032
- 6.3.2 Canada Dengue Vaccine Market Outlook, 2021- 2032
- 6.3.3 Mexico Dengue Vaccine Market Outlook, 2021- 2032
- 7. Europe Dengue Vaccine Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Dengue Vaccine Market Trends and Growth Opportunities
- 7.2.1 Europe Dengue Vaccine Market Outlook by Type
- 7.2.2 Europe Dengue Vaccine Market Outlook by Application
- 7.3 Europe Dengue Vaccine Market Outlook by Country
- 7.3.2 Germany Dengue Vaccine Market Outlook, 2021- 2032
- 7.3.3 France Dengue Vaccine Market Outlook, 2021- 2032
- 7.3.4 The UK Dengue Vaccine Market Outlook, 2021- 2032
- 7.3.5 Spain Dengue Vaccine Market Outlook, 2021- 2032
- 7.3.6 Italy Dengue Vaccine Market Outlook, 2021- 2032
- 7.3.7 Russia Dengue Vaccine Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Dengue Vaccine Market Outlook, 2021- 2032
- 8. Asia Pacific Dengue Vaccine Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Dengue Vaccine Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Dengue Vaccine Market Outlook by Type
- 8.2.2 Asia Pacific Dengue Vaccine Market Outlook by Application
- 8.3 Asia Pacific Dengue Vaccine Market Outlook by Country
- 8.3.1 China Dengue Vaccine Market Outlook, 2021- 2032
- 8.3.2 India Dengue Vaccine Market Outlook, 2021- 2032
- 8.3.3 Japan Dengue Vaccine Market Outlook, 2021- 2032
- 8.3.4 South Korea Dengue Vaccine Market Outlook, 2021- 2032
- 8.3.5 Australia Dengue Vaccine Market Outlook, 2021- 2032
- 8.3.6 South East Asia Dengue Vaccine Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Dengue Vaccine Market Outlook, 2021- 2032
- 9. South America Dengue Vaccine Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Dengue Vaccine Market Trends and Growth Opportunities
- 9.2.1 South America Dengue Vaccine Market Outlook by Type
- 9.2.2 South America Dengue Vaccine Market Outlook by Application
- 9.3 South America Dengue Vaccine Market Outlook by Country
- 9.3.1 Brazil Dengue Vaccine Market Outlook, 2021- 2032
- 9.3.2 Argentina Dengue Vaccine Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Dengue Vaccine Market Outlook, 2021- 2032
- 10. Middle East and Africa Dengue Vaccine Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Dengue Vaccine Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Dengue Vaccine Market Outlook by Type
- 10.2.2 Middle East and Africa Dengue Vaccine Market Outlook by Application
- 10.3 Middle East and Africa Dengue Vaccine Market Outlook by Country
- 10.3.1 Saudi Arabia Dengue Vaccine Market Outlook, 2021- 2032
- 10.3.2 The UAE Dengue Vaccine Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Dengue Vaccine Market Outlook, 2021- 2032
- 10.3.4 South Africa Dengue Vaccine Market Outlook, 2021- 2032
- 10.3.5 Egypt Dengue Vaccine Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Dengue Vaccine Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- Biological E Ltd
- GeneOne Life Science Inc
- GlaxoSmithKline Plc
- Medigen Vaccine Biologics Corp
- Merck & Co. Inc
- Panacea Biotec Ltd
- Sanofi Pasteur Ltd
- Serum Institute of India Pvt. Ltd
- Sun Pharmaceutical Industries Ltd
- Takeda Pharmaceutical Company Ltd
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
